
SenzaGen AB
SENZA · ST · Healthcare / Diagnostics & Research
Price History
Full chartMarket Stats
About
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices. In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, skin sensitization, and skin absorption; and eye irritation, phototoxicity, and cytotoxicity testing services and advisory services to pharma, medial devices, cosmetics, an chemical industries. Further, it provides SenzaGen, a test portfolio to assess toxicity of chemicals, cosmetics, medical devices, drug candidates, and nutrition/food additives. The company offers services through license partners and distributors. It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization. SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden.
Company Details
- SectorHealthcare
- IndustryDiagnostics & Research
- CEOMr. Peter Nahlstedt
- Employees34
- HeadquartersBuilding 401, Lund, Sweden, 223 81, Sweden
- Websitehttps://senzagen.com
Leadership
- Mr. Peter NahlstedtPresident & CEO · b. 1974
- Ms. Marianne OlssonVice President of Finance · b. 1961
- Dr. Henrik JohanssonChief Scientist · b. 1982
- Ms. Tina Dackemark LawessonVice President of Marketing & Communications · b. 1968
- Mr. Andy ForrerydVice President of Sales · b. 1984
- Ms. Helen OlssonVice President of HR · b. 1965